文献速递乳腺癌放疗

T1-T2期及1-3枚阳性淋巴结乳腺癌患者乳房切除术后放疗:BIG 02-98试验分析

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-02-06

基于BIG 02-98试验中684例T1-T2期、1-3枚阳性淋巴结且行乳房切除加腋窝淋巴结清扫的患者,337例(49%)接受PMRT。10年局部区域复发风险PMRT组2.5% vs 无PMRT组6.5%(HR 0.29,95%CI 0.12-0.73;结论认为PMRT可改善LRR但事件数少,应个体化决策。

要点

  • 乳腺癌特异生存(84.3% vs 83.9%)与总生存(81.7% vs 78.3%)无显著差异。

核心结论

  • 在T1-T2期、1-3枚阳性淋巴结且行腋窝淋巴结清扫的患者中,PMRT改善局部区域复发但10年事件数仍低,应基于个体风险决定PMRT。

研究设计与样本

  • BIG 02-98试验中PMRT为非随机、按机构偏好实施;本分析纳入684例T1-T2期、1-3枚阳性淋巴结且行乳房切除加腋窝淋巴结清扫的患者,其中337例(49%)接受PMRT。

主要发现

  • 乳腺癌特异生存PMRT组84.3% vs 无PMRT组83.9%,总生存81.7% vs 78.3%,均无显著差异。

关键数值与推荐

  • 乳腺癌特异生存84.3% vs 83.9%,总生存81.7% vs 78.3%。

临床怎么用

  • 对T1-T2期、1-3枚阳性淋巴结且行腋窝淋巴结清扫的患者,PMRT可降低LRR但绝对事件数低,应结合个体复发风险选择是否放疗。

局限性

  • PMRT为非随机、按机构偏好实施,存在选择偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. METHODS AND MATERIALS: The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence (LRR), breast cancer-specific survival, and overall survival. RESULTS: We identified 684 patients who met the inclusion criteria and were included in the analysis, of whom 337 (49%) had received PMRT. At 10 years, LRR risk was 2.5% in the PMRT group and 6.5% in the no-PMRT group (hazard ratio 0.29, 95% confidence interval 0.12-0.73; P = .005). Lower LRR after PMRT was noted for patients randomized to receive adjuvant chemotherapy with no taxane (10-year LRR: 3.4% vs 9.1%; P = .02). No significant differences in breast cancer-specific survival (84.3% vs 83.9%) or overall survival (81.7% vs 78.3%) were observed according to receipt of PMRT. CONCLUSION: Our analysis of the BIG 02-98 trial shows excellent outcomes in women with T1-T2 tumors and 1 to 3 positive lymph nodes found in axillary dissection. Although PMRT improved LRR in this cohort, the number of events remained low at 10 years. In all groups, 10-year rates of LRR were relatively low compared with historical studies. As such, the use of PMRT in women with 1 to 3 positive nodes should be tailored to individual patient risks.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zeidan YH, Habib JG, Ameye L, et al. Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018. PMID: 29534902. doi:10.1016/j.ijrobp.2018.01.105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。